ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CLRB / insiders
ASBP (40) LSTA (29) GTBP (36) LPCN (23) ⌘ Pro Terminal β†’

Cellectar Biosciences Inc. (CLRB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.22 +1.25% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.22

Cellectar Biosciences Inc. (CLRB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $11.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLRB Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CLRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Cellectar Biosciences Inc. (NASDAQ: CLRB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.22 (+1.25% 1D, market cap $11.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLRB ranks #739 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CLRB compare to ASBP and LSTA in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLRB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ASBP (Aspire-Lakewood Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.4M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, CLRB leads on earnings multiple (N/A) while CLRB leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLRB?
β–Ό

Per CLRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001279704), Cellectar Biosciences Inc. generated $64.3M in revenue (-55.6% YoY), -$21.8M in net income, and -$23.1M in free cash flow against $15.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.22 (+0.03%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (6)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.5% Base Target
$5 Bull$1 Base$1 Bear
πŸ“¬ FREE CLRB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CLRB)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY CLRB SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime Γ— Technicals: 3% of 52W Range β€’ RSI-14 at 30.7 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$1.39-11.5% Next Q
Q2 (-2Q)
37
Grade E$1.23-1.6% Next Q
Q3 (-1Q)
35
Grade E$1.21+0.8% Next Q
Current
32
Grade E$1.22-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CLRB Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CLRB currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.83) and Max Pain ($1.28) forces dealer call-delta covering toward $4.94.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLRBβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCLRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

CLRB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CLRB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CLRB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLRB)

  • βœ“Walkthrough of CLRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CLRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.89%β–Ό DESCENDING CHANNEL
2026-11-03O $1.22H $1.22L $1.21C $1.22VOL 55.3K
RES: $2.12SUP: $0.77SMA50: $1.83SMA200: $2.61
$4.95$3.91$2.87$1.84$0.80RES $2.12SUP $0.77$1.222026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CLRB Butterfly Map β†’ + Track CLRB β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -55.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLRB today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CLRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLRB)

Health Care Rank #739 of 1015 βš”οΈ ASBP vs CLRB Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CLRB vs. ASBP, LSTA, GTBP, LPCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cellectar Biosciences Inc. (CLRB) ranks #739 by composite RQD confidence (32/100, grade E) and #880 by equity capitalization ($11.4M). Within this direct 5-issuer industry benchmark cohort, CLRB leads on earnings valuation at N/A trailing P/E, while CLRB leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. ASBP currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with CLRB at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLRB ACTIVE
Cellectar Biosciences Inc.
E 32/100 β€” β€” -35.0% +1.25% $11.4M Benchmark Subject
ASBP
Aspire-Lakewood Holdings Inc.
D- 40/100 β€” -1.9% -35.0% -9.99% $11.4M /asbp-vs-clrb β†’
LSTA
Lisata Therapeutics Inc.
E 29/100 β€” β€” -35.0% -0.98% $11.0M /lsta-vs-clrb β†’
GTBP
GT Biopharma Inc.
D- 36/100 β€” β€” -35.0% -3.57% $11.0M /gtbp-vs-clrb β†’
LPCN
Lipocine Inc.
E 23/100 β€” β€” -35.0% +0.69% $11.9M /lpcn-vs-clrb β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001279704 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cellectar Biosciences Inc. (CLRB) reported GAAP revenue of $64.3M (-55.6% vs. FY2024 revenue of $145.0M , and -41.0% cumulative change since FY2023) , GAAP net income of -$21.8M, operating cash flow of -$23.1M, and free cash flow of -$23.1M (+51.5% YoY). On the balance sheet, CLRB closed FY2025 with $15.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $64.3M -$21.8M -$23.1M -$23.1M $15.0M β€”
FY2024 (FY) 2024-12-31 $145.0M -$44.6M -$47.6M -$47.7M $25.5M β€”
FY2023 (FY) 2023-12-31 $109.1M -$38.0M -$32.4M -$32.4M β€” β€”

3. CLRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cellectar Biosciences Inc. (NASDAQ: CLRB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.22 (+1.25% 1D, market cap $11.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLRB ranks #739 in composite RQD confidence.

How does CLRB compare to ASBP and LSTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLRB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ASBP (Aspire-Lakewood Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.4M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, CLRB leads on earnings multiple (N/A) while CLRB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLRB?

Per CLRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001279704), Cellectar Biosciences Inc. generated $64.3M in revenue (-55.6% YoY), -$21.8M in net income, and -$23.1M in free cash flow against $15.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLRB trading relative to its 50-day, 200-day, and 52-week technical levels?

CLRB last traded at $1.22 (+1.25% on volume of 66,554 shares), positioning the stock -33.33% below its 50-day simple moving average ($1.83) and -53.26% below its 200-day simple moving average ($2.61). Across its 52-week range of $1.12 to $4.70, CLRB sits at the 2.8% percentile with a 14-day RSI of 30.7 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.07 to $1.37).

Direct Sub-Reports: CLRB RQD Cockpit CLRB 12M Forecast CLRB Earnings & Move CLRB Dividends & DRIP CLRB Insiders & 13F CLRB Whale Options CLRB Profit Sankey CLRB News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

CLRB β€” Cellectar Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cellectar Biosciences Inc. (CLRB) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.22 (+1.25% 1D, market capitalization $11.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cellectar Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B in that record, which conflicts with the $11.5M shown in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cellectar Biosciences Inc. (CLRB) reported $64.3M in annual revenue (up from $145.0M in FY2024, -55.6% YoY) and -$21.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($109.1M revenue, -$38.0M net income) through FY2025, CLRB scaled operating cash flow to -$23.1M and free cash flow to -$23.1M, backed by $15.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.12 – $4.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE and the butterfly_links array is empty, so no upstream or downstream dependencies are mapped. Sector correlations beyond the Health Care classification are β€” Second-order bottlenecks cannot be identified from the provided graph.

  • Key Question #1: Can CLRB sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $64.3M and free cash flow of -$23.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLRB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLRB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cellectar Biosciences Inc. (CLRB) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CLRB Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLRB Bull vs. Bear Conversation Board β€” What's Your Call at $1.22?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLRB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLRB:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $1.60 (+32.2%)
πŸ“Œ Pinned Debate

A reported complete response lasting more than eight years in a heavily pretreated DLBCL patient treated with Iopofosine I 131 is the m

Long CLRB at $1.21 targeting $1.60. A reported complete response lasting more than eight years in a heavily pretreated DLBCL patient treated with Iopofosine I 131 is the most prominent positive catalyst in the news wire.. Institutional whale score is 3/20 and the risk/reward vs. the $1.12 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” CLRB's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.03 (-14.9%)
Spot @ $1.21

With $0.0M revenue, -35% ROIC, a 0% FCF yield, and a Piotroski F of 2 out of 9, the financials show no cash generation to support the $

Sitting on the sidelines or leaning short CLRB above $1.21. With $0.0M revenue, -35% ROIC, a 0% FCF yield, and a Piotroski F of 2 out of 9, the financials show no cash generation to support the $11.5M market capitalization.. Until Fundamental Cash Engine (6/20) and FCF yield (0.0%) inflect higher, upside is capped near $4.70.

LIVE TAPE